American International Group Inc. boosted its position in Axovant Sciences Ltd. (NYSE:AXON) by 7.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,052 shares of the biotechnology company’s stock after buying an additional 998 shares during the period. American International Group Inc.’s holdings in Axovant Sciences were worth $225,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in Axovant Sciences during the fourth quarter worth $139,000. Wells Fargo & Company MN raised its stake in Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock worth $335,000 after buying an additional 5,733 shares during the period. Woodstock Corp raised its stake in Axovant Sciences by 55.0% in the first quarter. Woodstock Corp now owns 35,003 shares of the biotechnology company’s stock worth $523,000 after buying an additional 12,417 shares during the period. Norges Bank bought a new position in shares of Axovant Sciences during the fourth quarter worth approximately $508,000. Finally, Teachers Advisors LLC increased its position in shares of Axovant Sciences by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock worth $513,000 after buying an additional 2,038 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.
Axovant Sciences Ltd. (NYSE:AXON) traded down 1.90% during trading on Wednesday, hitting $22.20. 45,941 shares of the stock were exchanged. The stock’s market cap is $2.36 billion. The stock’s 50 day moving average price is $22.86 and its 200 day moving average price is $19.36. Axovant Sciences Ltd. has a 12 month low of $11.01 and a 12 month high of $26.49.
Axovant Sciences (NYSE:AXON) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.12. Analysts forecast that Axovant Sciences Ltd. will post ($2.41) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/16/axovant-sciences-ltd-nyseaxon-position-boosted-by-american-international-group-inc-updated-updated.html.
AXON has been the topic of a number of research analyst reports. Jefferies Group LLC restated a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research note on Friday, June 9th. CIBC upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. Oppenheimer Holdings, Inc. upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 14th. BidaskClub upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Finally, Zacks Investment Research downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Axovant Sciences presently has an average rating of “Buy” and an average target price of $28.50.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
